**Core Concept**
Chronic gout requires urate-lowering therapy (ULT) to prevent renal impairment and cardiovascular events. In patients with renal insufficiency, the choice of ULT is crucial to avoid further kidney damage.

**Why the Correct Answer is Right**
The correct answer is **Febuxostat**, a non-purine xanthine oxidase inhibitor that is primarily metabolized by the liver and does not require dose adjustment in renal insufficiency. It is an effective and well-tolerated option for ULT in patients with chronic gout and impaired renal function.

**Why Each Wrong Option is Incorrect**
**Option A:** Allopurinol is a purine xanthine oxidase inhibitor that is primarily excreted by the kidneys. In patients with renal insufficiency, allopurinol can accumulate to toxic levels, increasing the risk of severe hypouricemia and other adverse effects.
**Option B:** Probenecid is a uricosuric agent that works by increasing uric acid excretion in the urine. However, it is contraindicated in patients with renal insufficiency, as it can worsen kidney function and increase the risk of hyperuricemia.
**Option C:** Colchicine is an anti-inflammatory medication used to treat acute gout attacks, but it is not an effective ULT and can have significant gastrointestinal side effects.

**Clinical Pearl / High-Yield Fact**
When choosing a ULT in patients with renal insufficiency, consider the pharmacokinetics and pharmacodynamics of each medication to minimize the risk of adverse effects and optimize efficacy.

**Correct Answer:** C. Febuxostat